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microRNAs (miRNAs) are emerging as crucial factors for the establishment of 
complex regulatory circuitries involved in the regulation of hematopoietic cell fate 
determination. These small non-coding RNAs to exert their functional activity are 
assembled in RNA-induced silencing complexes (RISCs), where a member of Argo-
naute (Ago) family of proteins plays a central role in miRNA-mRNA target interac-
tion and gene silencing. In human cells the miRNAs-Ago complex can also localize 
in the nucleus where Ago proteins can associate with promoter gene sequences to 
impact heterochromatin genomic structure and transcriptional silencing (Janowski BA 
et al., 2006; Meister G., 2013).
By using human myeloid cell lines and acute myeloid leukemia (AML) prima-
ry blasts we highlight Ago2 as a new player in myeloid cell fate determination. We 
observed that: i) Ago2 protein levels are strongly increased during 1,25-dihydroxyvi-
tamin D3 (D3)-induced monocyte differentiation, whereas are down-regulated during 
Retinoic Acid (RA)-induced granulocyte differentiation; ii) Ago2 depletion by shRNA 
or small chemical compounds disrupting both miRNA-Ago2 complex interaction and 
Ago2 chromatin localization, results in a strong improvement of the RA-dependent 
myeloid differentiation. 
These results are bringing out that the down-regulation of Ago2 expression/func-
tional activity is required during RA-dependent myeloid differentiation and may rep-
resent a molecular determinant for the improvement of RA-treatment response in leu-
kemic myeloid progenitors cells.
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